As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? | The Motley Fool
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.

Source: The Motley Fool
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.